Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen KYPROLIS (carfilzomib by Quarter
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%) (%)
Amgen KYPROLIS (carfilzomib: 8.0% in Q3 2023, down 3.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q3 2023 figure comes from
“KYPROLIS ® (carfilzomib) sales increased 10% year-over-year for the third quarter, primarily driven by 8% volume growth.”
Source: Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2023 | Sep 30, 2023 | 8.0% | -3.0 pts | Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 15.0% | -4.0 pts | Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 18.0% | +5.0 pts | Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 11.0% | +1.0 pts | Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 19.0% | – | Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 13.0% | – | Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 10.0% | – | Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗ |
Cite this data
StockData. (2026). Amgen KYPROLIS (carfilzomib (%), quarterly Q3 2021–Q3 2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kyprolis-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.